Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01704365 · ClinicalTrials.gov registry record · Phase 2
RSV-F Vaccine Dose Ranging Study in Young Women
A Phase 2 study, sponsored by Novavax.
- Completed
- Registry status
- Phase 2
- Development phase
- 330
- Enrollment target
NCT01704365 is a Phase 2 study that has completed, run by Novavax. The registered enrollment target is 330 participants.
The verdict
NCT01704365, a Phase 2 study, has completed, sponsored by Novavax.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 330 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the immunogenicty and safety of an RSV-F protein nanoparticle vaccine, with out without aluminum, in healthy women of child-bearing potential.
Interventions
- BIOLOGICAL Low dose RSV-F Vaccine with Adjuvant
- BIOLOGICAL Low dose RSV-F Vaccine without Adjuvant
- BIOLOGICAL High dose RSV-F Vaccine with Adjuvant
- BIOLOGICAL High dose RSV-F Vaccine without Adjuvant
- BIOLOGICAL Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01704365
The ClinicalTrials.gov registry entry for NCT01704365 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novavax, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Low dose RSV-F Vaccine with Adjuvant is the first listed.
NCT01704365 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01704365 about?
NCT01704365 is a clinical study titled "RSV-F Vaccine Dose Ranging Study in Young Women". The purpose of this study is to evaluate the immunogenicty and safety of an RSV-F protein nanoparticle vaccine, with out without aluminum, in healthy women of child-bearing potential.
What is the current status of trial NCT01704365?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 330 participants. The study started on 2012-10. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01704365?
The interventions under investigation include: Low dose RSV-F Vaccine with Adjuvant (BIOLOGICAL), Low dose RSV-F Vaccine without Adjuvant (BIOLOGICAL), High dose RSV-F Vaccine with Adjuvant (BIOLOGICAL), High dose RSV-F Vaccine without Adjuvant (BIOLOGICAL), Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing] (BIOLOGICAL).
Who is sponsoring clinical trial NCT01704365?
This trial is sponsored by Novavax, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.